1 **Adiposity, metabolites and endometrial cancer risk: Mendelian randomization and Observational**

- 2 **analyses**
- 3 Matthew A Lee^{1,2,3*}, Vanessa Y. Tan^{1,2*}, Dimitri J Pournaras⁴, Sabrina Wang³, Laure Dossus³, Marc J.
- 4 Gunter^{3,5}, Kaitlin H. Wade^{1,2}, Laura J. Corbin^{1,2}, Nicholas J. Timpson^{1,2}
- 5 ^{*} These authors contributed equally to this work
- 6 ¹Medical Research Council (MRC) Integrative Epidemiology Unit, Population Health Sciences, Bristol
- 7 Medical School, University of Bristol, Bristol, United Kingdom.
- 8 Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
- $9³$ International Agency for Research on Cancer, World Health Organization, Lyon, France
- 10 ⁴ Department of Upper GI and Bariatric/Metabolic Surgery, North Bristol NHS Trust, Southmead Hospital,
- 11 Bristol, UK.
- ⁵ Cancer Epidemiology and Prevention Research Unit, School of Public Health, Imperial College London,
- 13 United Kingdom.
- 14
- 15 **Corresponding author:** Professor Nicholas J. Timpson, Address: MRC Integrative Epidemiology Unit,
- 16 University of Bristol, Oakfield House, Oakfield Grove, Bristol, BS8 2BN, email: N.J.Timpson@bristol.ac.uk
- 17 **Key words:** Adiposity, Metabolites, Endometrial cancer, Mendelian randomization
- 18 **Main text words:** 4,279 ; **Abstract:** 417 ; **References:** 55 ; **Tables & Figures:** 9 ; **Supplementary files:** 4

Abstract

Introduction

 Increased and excess adiposity is associated with increased risk of endometrial cancer (EC) 22 and both of these are associated with circulating metabolite profiles. However, how metabolites relate to the adiposity-EC relationship remains unclear.

Methods

 We have brought together evidence from Mendelian randomization (MR) and observational analyses to evaluate the effect of i) adiposity traits on endometrial cancer, ii) adiposity traits on circulating metabolites and iii) adiposity-associated metabolites on EC. We have also evaluated the potential role of metabolites in the adiposity-EC relationship using multivariable MR. Observational analyses were conducted using individual level data from UK Biobank (N = 1,005 cases and 215,339 controls). MR analyses were performed using female- specific summary statistics from genome-wide association studies of body mass index (BMI; N up to 434,794), waist-to-hip ratio (WHR; N up to 381,152), 249 metabolites and ratios from targeted nuclear magnetic resonance metabolomics (N up to 140,768) and EC risk (12,906 cases and 108,979 controls).

Results

 In observational analyses, higher BMI and WHR were associated with elevated odds of overall EC (odds ratio (OR) per standard deviation (SD) increase in BMI = 1.37; 95% confidence interval (CI) = 1.19, 1.57; OR per SD increase in WHR= 1.15; 95% CI = 1.01, 1.32). In MR analysis, higher BMI was associated with elevated odds of overall EC risk (OR per SD increase in BMI = 1.80; 95% CI = 1.56, 2.07), endometrioid cancer (OR = 1.71; 95% CI = 1.45, 2.02) and non-endometrioid cancer (OR = 2.20; 95% CI = 1.55, 3.12). There was weaker evidence for a causal relationship with WHR. BMI was associated with 165 metabolites and ratios after Bonferroni-correction in MR analyses, several of which were associated with EC and 25 of which were directionally consistent with an intermediate role in the effect of BMI on EC risk from two-step MR and observational analyses. In MVMR analyses, there was evidence suggesting that the effect of BMI on non-endometrioid EC was mediated by several lipid metabolites; for example, the univariable MR OR for non-endometrioid EC per 1 SD increase

 in BMI was 2.51 (95%CI = 1.47, 4.29), whereas on adjusting for free cholesterol to total lipids ratio in medium LDL, the MVMR OR for non-endometrioid EC per 1 SD increase in BMI was 1.18 (95%CI = 0.53, 2.66). Further bioinformatic analyses highlighted a mixture of other potential shared pathways (including height, adiposity traits and blood cell traits) that could influence the risk of EC.

Conclusion

 Evidence here suggests that higher BMI causes a higher risk of overall and all histological subtypes of EC and variation in numerous circulating metabolites. Several of these metabolites showed relationships consistent with an intermediate role between BMI and non-endometrioid EC, however, further bioinformatic analyses highlighted other potential shared mechanisms that could influence the risk of EC.

-
-
-
-
-
-
-
-

69 **Introduction**

70 Endometrial cancer (EC; cancer of the lining of the uterus) is the most common gynaecological 71 cancer among women with more than 380,000 new cases diagnosed globally¹. Based on 72 differences in histology and clinical outcomes, there are two main subtypes of EC: 73 endometrioid carcinomas (type 1 tumours) with good prognosis and non-endometrioid 74 carcinomas (type 2 tumours) with worse prognosis². Endometrioid EC is more commonly 75 hormonally driven compared with non-endometrioid $EC³$.

76

The Excess body weight is robustly associated with EC, with support from observational studies⁴. 78 Mendelian randomisation⁵ (MR) studies, which use genetic variants as instruments (or 79 proxies), of adiposity traits further support the evidence base for a causal relationship with 80 EC^{6-8} . However, whilst the relationship between adiposity and EC is well-established, 81 understanding of the mechanisms and covariables involved in the adiposity-EC relationship 82 remains incomplete. Furthermore, evidence of associations between body fat distribution, 83 measured as waist-hip-ratio (WHR), has only been supported with observational studies^{4,6,8}.

84

85 Metabolic reprogramming is recognised as a hallmark of tumorigenesis⁹ and there is evidence 86 that metabolic dysfunction drives the development and progression of $EC^{10,11}$. Findings from 87 a recent prospective study suggest that concentrations of glycine, serine, sphingomyelin and 88 free carnitine may represent specific pathways involved in EC development¹². Increased 89 adiposity causes changes to an individual's systemic metabolic profile^{13–15}. Observational and 90 MR studies support an effect of adiposity (proxied using body mass index [BMI]), on raised 91 amino acids, fatty acids and inflammatory glycoprotein acetyls¹⁵, leading to suggestions that 92 a potential mechanism linking adiposity and EC could be adiposity-induced metabolic 93 \cdot changes¹⁰. A recent prospective study showed that EC is positively associated with adiposity-94 associated metabolic changes including specific amino acids and lipids¹⁶; however, whether 95 these relationships are causal is unclear.

96

97 We aimed to better understand the potential role of circulating metabolites as intermediates 98 in the association between adiposity and EC risk by triangulating evidence from summary-

99 level univariable two-step¹⁷ MR and multivariable MR approaches in combination with observational analyses in UK Biobank.

Methods

Analytical strategy

 This study has four main analyses that were performed sequentially (**Figure 1**) to estimate: (**Part I**) the effect of adiposity measures on EC, (**Part II**) the effect of adiposity measures on circulating metabolites, (**Part III**) the effect of adiposity-associated metabolites on EC, and (**Part IV**) the potential intermediate role of adiposity-associated metabolites in the relationship between adiposity and EC (identified in **Part II** and **III**). Observational analyses were performed for Parts I-III. MR analyses were performed for Parts I-IV; Metabolite data from UK Biobank were used in both the MR and observational analyses. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 112 and STROBE-MR guidelines (Supplementary Table S1 and S2)^{18,19}.

Observational analyses (Part I-III)

Study population

 UK Biobank is a nation-based health project that recruited more than 500,000 participants 117 (aged 37-73 years, 56.3% were women) between 2006 and 2020 20,21 . In addition to the collection of biological samples (blood, saliva and urine), health, demographic and anthropometric data were collected in 22 assessment facilities across England, Wales and 120 Scotland²². Participants provided written informed consent. Ethical approval was obtained from the Northwest Multi-centre Research Ethics Committee (11/NW/0382). Data from UK Biobank were accessed via application number 16391 and 30418. Data for adiposity measures 123 and endometrial cancer outcome was extracted on the $08/07/2021$ and the 1 H-NMR metabolite data was extracted on the 08/02/2023.

Adiposity measures

127 BMI was calculated as weight (kg)/height² (m²) and WHR as waist circumference (cm)/hip circumference (cm). Height was measured to the nearest centimetre, using a Seca 202 129 stadiometer, and body weight to the nearest 0.1kg, using a Tanita BC-418 body composition

130 analyser. Waist circumference was measured at the natural indent (the umbilicus was used if the natural indent could not be observed); hip circumference was measured at the widest 132 part of the hips. BMI and WHR were inverse rank normal transformed prior to observational analyses and represent normalised SD units.

Metabolite measures

 Non-fasting EDTA plasma samples were collected from approximately 275,000 participants, a 137 random subset of the original ~500,000, who provided samples at the 2006-2010 assessment (N=275,000) or at a subsequent assessment in 2012-2013 (N=17,000) (around 15,000 of these have both baseline and repeat assessment). A total of 249 metabolic traits (168 140 concentrations plus 81 ratios) were quantified using 1 H-NMR spectroscopy (data pre- processing and quality control steps conducted by Nightingale Health are described 142 previously^{23,24}). Inverse rank normal transformed metabolite concentrations were used in all analyses and represent normalised SD units.

Endometrial cancer

 EC was defined as a malignant neoplasm of the endometrium. The UK Biobank database contained a record of all cancers including their subtype occurring either before or after 148 participant enrolment using the International Classification of Diseases, $9th$ and $10th$ revision (ICD-10, ICD-9). The following ICD-10 and ICD-9 codes were used to define EC: ICD10 codes (C540, C541, C542, C543, C549 and C55) and ICD9 codes (179, 1799, 180, 182, 1820, 1821 and 1828). Cases were characterised as incident or prevalent using 'age when they attended the centre' and 'age when first reported EC cancer'. Participants were defined as incident cases if their 'attending age' was less than their 'cancer diagnosis age'. In total, there were 1,935 EC cases with 1,005 being incident cases and 930 prevalent cases. Only incident cases (N=1,005) were included in our analyses. Controls (n=215,339) were defined as female participants who had no record of any type of cancer, in-situ carcinoma, or an undefined neoplasm.

Covariables

We included potential confounders of the BMI-metabolite-EC relationships in our analyses.

The potential confounders were sociodemographic factors (age at assessment, physical

 activity, smoking status, alcohol consumption and educational attainment) and female- specific factors (history of hormone replacement therapy (HRT) use, age at first live birth, age at last live birth, age at menarche and menopausal status). Age, smoking status, alcohol consumption, education attainment and female-specific factors were self-reported at the baseline assessment by questionnaire. Physical activity level over a typical week was self- reported using the International Physical Activity Questionnaire and reported as metabolic equivalent of task (MET) per week.

Statistical analyses

 Observational associations between: I) adiposity measures and EC (**Figure 1, Part I**) were assessed using multivariable logistic regression, II) adiposity measures and metabolites (**Figure 1, Part II**) were assessed using multivariable linear regression for cases and controls combined in one cohort and III) adiposity-associated metabolites and EC (**Figure 1, Part III**) were assessed using multivariable logistic regression. All analyses were initially adjusted for 175 age at assessment and centre. Models were additionally adjusted for potential confounders (smoking status, alcohol consumption, education status, physical activity, hormone replacement therapy use, age at first live birth, age at last live birth, age at menarche and menopausal status). To account for multiple testing, we used the Bonferroni-adjusted *p* value threshold (0.05/249) for the association between adiposity measures and metabolites and *p*- value < 0.05 for all other tests. Multivariable linear and logistic regression analyses were performed using the lm and glm functions, respectively, in R.

Genome-wide association study results and Mendelian randomisation analyses (Part I-IV)

Data sources and study populations

Adiposity instruments

 We identified single nucleotide polymorphisms (SNPs) that were independently associated 187 (low linkage disequilibrium (LD), R²<0.001) with BMI and WHR (unadjusted for BMI) at p <5x10⁻ 9 from a recent large-scale female-specific genome-wide association study (GWAS) meta- analysis of 434,794 female adults of European ancestries from the Genetic Investigation of 190 Anthropometric Traits (GIANT) consortium and the UK Biobank²⁵ (**Supplementary Table 3**). Adiposity measures were inverse rank normal transformed prior to genome-wide analysis and

 units therefore represent a normalised standard deviation (SD). In total, 271 (average F- statistic = 41) and 227 (average F-statistic = 45) SNPs were identified for BMI and WHR, respectively.

Metabolite GWAS in UK Biobank and selection of metabolite instruments

 A random subset of non-fasting baseline plasma samples, consisting of 275,000 UK Biobank participants and 17,000 repeat-visit samples (around 15,500 of these have both a baseline 199 and repeat assessment), were measured using targeted high-throughput $1H$ -Nuclear magnetic resonance (¹H-NMR) metabolomics (Nightingale Health Ltd; biomarker 201 guantification version 2020)^{24,26}. Genotype data was available for 488,377 individuals, of which 49,979 were genotyped using the UK BiLEVE array and 438,398 using the UK Biobank 203 axiom array. Pre-imputation QC, phasing and imputation have been described previously²¹. Genotype imputation was performed using IMPUTE2 algorithms²⁷ to a reference set 205 combining the UK 10K haplotype and HRC reference panels²⁸. Post-imputation QC was performed as described in the "UK Biobank Genetic Data: MRC-IEU Quality Control" documentation^{29,30}. We conducted a female-specific GWAS for the 249 ¹H-NMR-derived metabolites and ratios in UK Biobank female participants of European descent (N=140,768) 209 using the MRC IEU UK Biobank GWAS pipeline³⁰. We restricted the samples to individuals of European ancestry as defined by the largest cluster in an in-house k-means clustering of genetic ancestry data (K=4) after standard exclusions including withdrawn consent, mismatch 212 between genetic and reported sex and putative sex chromosome aneuploidy²⁹⁻³¹ (**Supplementary Table 3**). Metabolite measures were inverse rank normal transformed prior to genome-wide analysis and units therefore represent a normalised SD. Genome-wide association analysis was conducted using a linear mixed model (LMM) as implemented in 216 BOLT-LMM (v2.3)³². Population structure was modelled using 143,006 directly genotyped SNPs (MAF > 0.01; genotyping rate > 0.015; Hardy-Weinberg equilibrium p-value < 0.0001 and 218 LD pruning to an r2 threshold of 0.1 using PLINK(v2.00)). Genotype array and fasting time 219 were adjusted for in the model. We identified 11-167 independent SNPs (r^2 <0.001 and $220 p$ <5x10⁻⁸) for each of the ¹H-NMR-derived metabolites (average F-statistics: ranged from 40.6-81.6).

Endometrial Cancer GWAS data

224 We obtained SNP estimates from the largest GWAS (as log odds ratio (OR)) for EC to date⁸, including up to 12,906 cases and 108,979 controls from 13 studies (**Supplementary Table 3**). Of the 12,906 cases and 108,979 controls, 636 cases (5%) and 62,853 controls (58%) were from UK Biobank. Summary statistics were also available for the association between genetic variation and the EC subtypes, endometrioid (8,758 cases) and non-endometrioid (1,230 cases) cancer; both GWASs used the full set of controls (N = 108,979). None of the endometrial subtype cases were from UK Biobank. Histological subtypes of EC were confirmed based on pathology reports and detailed study descriptions have previously been reported⁸.

Statistical analysis

235 In each instance, MR estimates are interpreted as the change in outcome per SD unit change 236 in exposure. Estimates for metabolite outcomes reflect SD unit change, and estimates for EC 237 outcomes reflect odds ratios (OR). All analyses were performed using R version $3.5.3^{33}$. 238 Univariable MR analyses were performed using the TwoSampleMR (version 0.4.22) package²⁶. 239 Multivariable MR analyses were performed using the MVMR (version 0.3) package³².

 First, we examined the association between BMI and WHR with overall, endometrioid and non-endometrioid EC risk using summary-level data from female-specific GWAS of BMI, WHR and EC (**Figure 1, Part I**). Details of the SNPs included in each analysis, and proxies used (where SNPs were not available in the outcome data), are provided in **Supplementary Table 4**. 245 Summary statistics were harmonised using the harmonise data function within the 246 TwoSampleMR R package (version $0.4.22$)³³. Univariable causal estimates were combined 247 using the inverse-variance weighted (IVW) multiplicative random effects (IVW-MRE) model³⁴. Where possible (i.e., where there were three or more instruments), the assumption of no 249 pleiotropy among genetic instruments and outcomes were explored using MR-Egger³⁵, 250 weighted median³⁶ and weighted mode³⁷ estimators. These methods are sensitive to the effects of potential pleiotropy under different assumptions. No *p*-value threshold requirements were set for these methods and, instead, consistency between the IVW model and the three sensitivity MR methods (MR-Egger, weighted median and weighted mode) was assessed.

 Second, adiposity traits(BMI and WHR) that showed evidence of an effect on EC with *p* values 257 < 0.05 from IVW-MRE models and with consistent associations across the three sensitivity MR methods, were taken forward and examined for associations with the 1 H-NMR-measured metabolites (**Figure 1, Part II**). Summary-level data were obtained from a female-specific GWAS for adiposity traits and ¹H-NMR metabolites, and we examined the effect of adiposity traits on ¹H-NMR-measured metabolites using the four MR models described above. Metabolites that were associated with the adiposity traits with *p* values < 0.05/249 (Bonferroni-adjusted *p*-value threshold) from IVW-MRE models were taken forward and 264 examined for association with EC risk using IVW-MRE model (if \geq 2) or Wald ratio (if 1 SNP) (**Figure 1, Part III**).

267 Multivariable MR (MVMR)^{38,39} was conducted to test the hypothesis that adiposity-associated metabolites (identified in **Part II and III**) may act as intermediate factors in the effect of BMI on EC (**Figure 1, Part IV**). Only metabolites that showed a consistent direction of effect across 270 the adiposity-EC, adiposity-metabolite, and metabolite-EC analyses from both MR and observational analyses (identified in **Part II and III**) were included in the MVMR analyses. For the MVMR analyses, we fitted a model with BMI and EC and included each BMI-associated metabolite in turn to estimate the direct causal effect of BMI on EC. We used female-specific 274 SNPs for BMI based on an earlier (lower-powered) GWAS⁴⁰ for the multivariable models to 275 avoid a relative dilution of metabolite instrument strength⁴¹ given that the number of SNPs for BMI from the latest BMI GWAS far outnumbered those for metabolites. Conditional F-277 statistics were used to evaluate instrument strength³⁹. Heterogeneity was quantified using an 278 adapted version of the Q statistic $(Q_{A_i},$ also a further modification of Cochran's Q)³⁹.

Sensitivity analyses

 Sample overlap between exposure and outcome GWAS can bias MR estimates towards the confounded observational estimate (inflated type 1 error) in the presence of weak instrument 283 bias in a manner proportional to the degree of overlap⁴². This bias can be inflated by "Winner's curse", in which weights for genetic instruments are derived from discovery samples that overlap with outcome samples. There was sample overlap across our MR analyses as the 286 adiposity, ¹H-NMR metabolite and EC GWAS all included participants from UK Biobank. Given

287 the random selection of samples for metabolomics analysis and the inclusion of almost all 288 samples within the adiposity GWAS it is not possible to precisely quantify the degree of 289 sample overlap but we make the assumption of 100% sample overlap between the adiposity 290 and ¹H-NMR metabolite GWAS. There was also approximately 5% overlap for both the 291 adiposity and ¹H-NMR metabolite GWAS with the overall EC GWAS. Given this, we conducted 292 sensitivity analyses to evaluate the influence of sample overlap in our MR analyses. First, for 293 analyses examining the association between adiposity traits with endometrial cancer risk 294 (**Figure 1, Part I**), we re-performed MR analyses using alternative GWAS data for BMI 295 (n=171,977) and WHR (N=118,004) where there was no sample overlap^{40,43} with either the EC 296 GWAS conducted by ECAC⁸ or an alternative EC GWAS conducted by ECAC which excluded UK 297 Biobank participants (personal correspondence) (N for overall EC=12,270 cases and 46,126 298 controls; N for endometrioid EC=8,758 cases and 46,126 controls and N for non-endometrioid 299 EC = 1,230 cases and 35,447 controls)⁸. Second, for analyses examining the association 300 between adiposity traits with ¹H-NMR metabolites (Figure 1, Part II), we re-performed MR 301 analyses using alternative GWAS data for BMI where there was no sample overlap^{40,43}. Third, 302 for analyses examining the association between ¹H-NMR metabolites and endometrial cancer 303 risk (**Figure 1, Part III**), we re-performed MR analyses using the alternative GWAS for EC which 304 had excluded UK Biobank participants⁸ (Supplementary Table 3).

305

306 **Examining off-target effects using PhenoScanner (Part V)**

 Due to the shared genetic architecture and pleiotropic nature of instruments for metabolites^{44–46}, it is possible for variants acting as proxies for metabolites to exert off-target or pleiotropic effects on EC through other biological mechanisms. This presents the possibility that intermediate associations are reflecting common, but unmeasured, biological underpinnings rather than more obvious hypothesised pathway effects. To investigate this, we assessed whether genetic instruments for adiposity- and EC-associated, (and apparently 313 intermediate) metabolites were associated with other traits (p <1E-10) in a manner different to that expected by chance given documented genotype/metabolite/trait associations. Using 315 PhenoScanner^{47,48}, we assessed the co-association of adiposity- and EC-associated metabolites with other phenotypes and outcomes before performing the same procedure over 100 iterations, but for randomly selected metabolites taken from the 244 metabolites not found to underlie the association between adiposity and EC risk. The overall profile of

- these redraws were compared with that from the adiposity- and EC-associated instruments,
- i.e. counts of detectable associations with trait domains for adiposity- and EC-associated
- instruments versus SNPs associated with random metabolites.
-

Results

Population and data overview

 The observational analyses within UK Biobank included up to 1,005 female participants who had a diagnosis of incident EC and up to 215,339 controls (**Table 1**). The cases and controls had a mean (SD) age of 59.63 (6.43) years and 55.83 (8.02) years, respectively. Mean BMI was 328 higher among cases than controls (at 30.33 kg/m² (7.07) and 27.06kg/m² (5.17), respectively). Mean WHR was higher among cases than controls (at 0.84 (0.07) and 0.82 (0.07), respectively). 3.66% reported having a diagnosis of diabetes, and this was more common among cases than controls (8.99% and 2.64%, respectively).

Association between adiposity measures and endometrial cancer (Part I)

 For BMI, observational analyses showed evidence that higher BMI (per SD) was associated with 1.61 (95% CI = 1.49, 1.75) times higher odds of overall EC; these results were consistent when adjusting for all covariables (OR = 1.37; 95% CI = 1.19, 1.57) (**Figure 2**; **Table 2**). This was supported by univariable MR analysis, which found that higher BMI (per SD) was associated with 1.80 (95% confidence interval (CI) = 1.56, 2.07) times higher odds of overall EC using the IVW-MRE model (**Figure 2; Supplementary Table 5**). Similar results were found for endometroid cancer (OR = 1.71; 95% CI = 1.45, 2.02) and non-endometrioid cancer (OR = 2.20; 95% CI = 1.55, 3.12) (**Supplementary Table 5**). This finding was consistent across sensitivity analyses using methods that consider potential genetic pleiotropy and when using instruments from non-overlapping samples (**Supplementary Table 5**).

 For WHR, observational analyses showed evidence that higher WHR (per SD) was associated with 1.23 (95% CI = 1.13, 1.34) times higher odds of overall EC; these results were consistent when adjusting for all covariables (OR = 1.15; 95% CI = 1.01, 1.32) (**Figure 2**; **Table 2**). Evidence 348 of association between WHR (per SD) and overall EC (OR = 1.10; 95% CI = 0.93, 1.29), endometroid EC (OR = 1.09; 95% CI = 0.91, 1.30) and non-endometrioid EC (OR = 1.43; 95% CI

 = 0.96, 2.12) in univariable MR was weaker (**Figure 2**; **Supplementary Table 5**). Sensitivity analyses were broadly consistent for overall and endometrioid EC. However, findings were less consistent for non-endometrioid EC in sensitivity analyses where the MR-Egger estimate (OR = 3.99; 95% CI = 1.14; 13.95) was greater in magnitude compared to the IVW estimates (**Supplementary Table 5**) and when using instruments from non-overlapping samples (IVW OR= 1.93; 95% CI = 1.17, 3.18) (**Supplementary Table 5**).

Association between adiposity measures and metabolites (Part II)

 Higher BMI (per SD) was associated with 175 metabolites after correcting for multiple testing and using the IVW-MRE model (**Figure 3**; **Supplementary Table 6**). Of these metabolites, 165 had consistent directions of effect in all four MR models and the fully-adjusted observational analyses (**Supplementary Figure 1 and 2**; **Supplementary Table 7)** and were taken forward for subsequent analysis with EC. These findings were broadly consistent across sensitivity analyses using instruments from non-overlapping samples (r=0.94) (**Supplementary Table 6**).

 BMI had a broad effect on the metabolomic profile, with associations across many metabolite classes including numerous lipid metabolites and their ratios such as total cholesterol, total lipids, triglycerides and cholesteryl esters in high density lipoprotein (HDL) and very low- density lipoprotein (VLDL). For example, higher BMI led to 0.40 SD (95% CI = 0.34, 0.46) and 0.39 SD (95% CI = 0.38, 0.39) lower levels of total cholesterol in very large HDL in MR and observational analyses, respectively. There was also evidence that higher BMI increased levels of several amino acids including valine, isoleucine, leucine, tyrosine, and phenylalanine (**Supplementary Table 6**). For example, higher BMI led to 0.23 SD (95% CI = 0.19, 0.27) and 0.26 SD (95% CI = 0.25, 0.27) higher levels of valine in MR and observational analyses, respectively.

Association between BMI-associated metabolites and endometrial cancer(Part III)

 Of the 165 BMI-associated metabolites, 25 metabolites (representing 27 adiposity- metabolite-EC associations) were directionally consistent with an intermediate role in the association between BMI and overall EC (2 associations), endometrioid EC (1 association) and non-endometrioid EC (24 associations) from MR analyses (**Figure 4 and Supplementary Figure**

 3; Supplementary Table 8). Observational analyses were only possible for overall EC. The two BMI-associated metabolites (phospholipid to total lipids ratio in medium VLDL and cholesteryl esters to total lipids ratio in medium HDL) had directions of effects consistent with MR analyses in the fully adjusted observational analysis (**Supplementary Table 9**).

 Of the 25 BMI-associated metabolites, 2 were associated with two EC outcomes in the MR analyses: phospholipids to total lipids ratio in medium VLDL was associated with overall (OR = 0.87; 95% CI = 0.75, 1.00) and endometrioid EC (OR = 0.85, 95% CI = 0.72, 0.99) and cholesteryl esters to total lipids ratio in medium HDL was associated with overall (OR = 0.86, 95% CI = 0.75, 0.98) and non-endometrioid EC (OR = 0.61, 95% CI = 0.44, 0.85). The remaining 23 metabolites - mainly of the lipoprotein subclasses - were associated with just one EC outcome, which was predominantly non-endometrioid cancer. For example, the largest positive and negative effects were observed for the association between cholesteryl esters to total lipids ratio in medium LDL (OR = 1.85; 95% CI = 1.15, 2.98) and total esterified cholesterol (OR = 0.57; 95% CI = 0.36, 0.90) and non-endometrioid cancer using the IVW-MRE model (**Figure 4**).

Examining the intermediate role of metabolites in the effect of adiposity on EC: Multivariable MR analyses (Part IV)

 We used MVMR to investigate whether the 25 BMI-associated metabolites were potential intermediates of the effect of BMI on EC risk. In MVMR, there was little evidence that the association of BMI with overall and endometrioid EC was strongly attenuated following adjustment for most metabolites (**Figure 5)**. For non-endometrioid EC, the association of BMI with non-endometrial cancer was attenuated following adjustment for various metabolites (**Figure 5**); for example, the univariable MR OR for non-endometrioid EC per 1 SD higher BMI was 2.51 (95%CI = 1.47, 4.29), whereas the MVMR OR for non-endometrioid EC per 1 SD increase in BMI was 1.18 (95%CI = 0.53, 2.66) after adjusting for free cholesterol to total lipids ratio in medium LDL. The conditional F statistics for BMI and metabolites instruments are presented in **Supplementary Table 10**.

Examining off-target effects

412 Given the highly pleiotropic nature of the metabolite instruments, it is possible that the instruments might be proxying other common, but unmeasured, biological pathways rather than having a direct effect through the metabolites. Using a commonly used catalogue of 415 genetic association results (PhenoScanner^{47,48}), we conducted a phenome scan for the genetic instruments proxying metabolites potentially underlying the adiposity-EC relationship and compared the traits association profiles with those of randomly selected metabolites. We identified a larger than expected proportion of instruments associated with several lipid traits including HDL, LDL, triglycerides and total cholesterol, as well as anthropometric (height and 420 adiposity) and blood cell traits for the metabolites underlying the adiposity-EC relationship compared to the randomly selected metabolites. This suggests that the metabolite 422 instruments could be proxying for or are a response read-out of other potentially shared biological pathways (**Figure 6**).

Discussion

 This study aimed to identify potential metabolic intermediates of the effects of adiposity on EC risk using MR and observational analyses. Higher BMI increased risk of overall EC and EC 428 stratified by histological subtypes. BMI was associated with numerous metabolites; 25 of which were also found to increase EC risk. There was evidence from both two-step and multivariable MR analyses that the effect of BMI on EC was mediated strongly by several lipid metabolites; however, further bioinformatic analysis highlighted numerous potential 432 pleiotropic and shared mechanisms that could potentially explain associations and patterns of intermediate effect.

Adiposity is a well-recognised risk factor for EC^{49-51} . Our analyses found that higher BMI and 436 WHR were positively associated with EC. In contrast, in MR analyses, we only found strong evidence that higher BMI increased EC risk. This is consistent with findings from recent MR studies where genetically elevated BMI, but not WHR, was found to be causally linked to $EC^{6,8,52,53}$. It is well-established in the literature that obesity is associated with both endometrioid and non-endometrioid EC, with stronger associations of an effect on 441 endometrioid EC, as compared to non-endometrioid $EC^{6,8,52,54-60}$. Interestingly, the effect of BMI on non-endometrioid EC was slightly greater than endometrioid EC in our study. 443 Although rarer, non-endometrioid tumours are more aggressive and have a poorer prognosis. Little is known about the etiology of non-endometrioid EC and the association with obesity warrants further investigation. WHR is widely used as a proxy measure of central adiposity and, notwithstanding variation in the statistical performance of analyses here and the impact 447 of measurement error and the genetic architecture of these traits on the nature of MR analyses, these findings may suggest that central adiposity may be less relevant for EC risk 449 than overall adiposity. This is supported by a recent MR study which found little evidence for a causal link between trunk fat ratio (proxy for abdominal adiposity) and EC but found strong evidence that BMI and arm fat ratio (proxy for overall body fat) had a strong positive effect on EC⁵³.

454 Adiposity leads to perturbations in systemic metabolism which may have an impact on $EC^{16,61}$. In both MR and observational analyses, BMI was associated with a wide array of metabolites; the effect estimates for a majority of metabolites (including HDL, VLDL, triglycerides, apolipoproteins A and B, glycolysis-related metabolites and amino acids) were generally 458 consistent in terms of direction and magnitude with previous studies^{15,41,62,63}; however, the associations of BMI with several metabolites including LDL cholesterol, total cholesterol, 460 sphingomyelin and fatty acids were inconsistent with patterns previously observed in an MR study conducted in young adults¹⁵. For example, our study found evidence of an inverse effect of BMI on LDL cholesterol which is in contrast to the previous MR study¹⁵ which supported a positive effect of BMI. It has been suggested that the inconsistencies could be partly attributable to higher prevalence of statin use in UK Biobank (22% of men and 12% of women)⁶².

 Of the BMI-associated metabolites, 25 metabolites were also associated with either overall, endometrioid or non-endometrioid EC. Our two-step and multivariable MR suggested that several lipid metabolites - the majority of which were metabolite ratios - could be potential intermediates between BMI and non-endometrioid EC risk. Cholesterol is an essential structural component of cell membranes and altered cholesterol metabolism can drive the onset and progression of cancer⁶⁴. In the circulation and within cells, free cholesterol is converted to cholesteryl esters (CE) by acylCoA-cholesteryl-acyl-transferase (ACAT). Numerous studies have shown that increased expression and activity of ACAT and subsequent accumulation of cholesteryl esters in cancer cells is linked to the development and progression of cancers, including endometrial cancer $65,66$. We did not find strong evidence that total cholesterol esters attenuated the effect of BMI on non-endometrioid EC risk in our MVMR analyses. Interestingly, we found evidence that cholesteryl esters to total lipids ratio in small and medium LDL were positively associated with both BMI and non-endometrioid EC risk while free cholesterol to total lipids ratio in medium and large LDL were inversely associated with BMI and in turn associated with reduced risk of non-endometrioid EC. These 482 metabolite ratios could represent flux through a biochemical pathway⁶⁷ and further studies could be conducted to investigate their role in the development of EC.

 Triglycerides, a major component of adipose tissues, are often elevated in adiposity and have 486 been suggested to drive EC development either directly or indirectly through deregulation of 487 peroxisome proliferator-activated receptors (PPARs)⁶⁸. We observed that triglycerides in LDL and triglycerides to total lipids ratio in VLDL, LDL and LDL particles were positively associated with both BMI and non-endometrioid endometrial cancer risk. The positive relationship 490 between triglycerides and endometrial cancer risk is consistent with several observational studies^{68–71}; however, a recent Mendelian randomization analysis study found little evidence 492 of a causal link between the role of triglycerides in the development of both endometrioid 493 and non-endometrioid EC^{72} . To this end, further research is required to clarify the role of triglycerides in non-endometrioid EC development.

 Understanding how metabolites may be potential intermediates between risk factors and disease outcomes is a compelling research topic. However, major challenges persist for identifying instruments to proxy circulating metabolites due to the complex genetic 499 architecture of blood metabolites $44-46$. First, owing to the high correlational structure of many metabolites, instruments for metabolites are often associated with other metabolites $46,73$. Second, due to the high degree of pleiotropy (or basic biological overlap) for metabolite instruments with other modifiable risk factors and disease endpoints, it is often not straightforward to determine the exact molecular mechanism by which they impact the outcome. Indeed, when considering whether we are reliably instrumenting the effect of BMI-

 associated metabolites on EC, we identified other shared pathways including height and several adiposity and blood cell traits that could influence associations with EC. This suggests that when compared with a (hypothetically null) set of randomly selected metabolites, instruments for implicated metabolites could be flagging biological pathways that may be driving causal associations; however, importantly, it is difficult to distinguish whether the biological pathways highlighted are due to vertical pleiotropy (i.e., the mechanism by which the SNP influences the outcome is via metabolites) or horizontal pleiotropy (i.e., the SNP could influence the outcome through a pathway independent of metabolites). Our approach to the examination and characterisation of signal metabolites is conceptually similar to a cis- versus-trans MR analysis of proteins that looks to clarify inference from MR methods through prior information available on the instruments in question. Using this approach, a recent study⁷⁴ demonstrated that the observed relationship between small HDL particle count and sepsis were - in part - driven by potential confounding between interleukin 6 (IL-6) and HDL, where IL-6 signalling is the true mechanism.

 This work adds to the body of evidence suggesting a causal relationship between adiposity and adiposity-associated metabolites with overall, endometrioid, and non-endometrioid EC 522 risk. In our study, we focussed predominantly on lipid-based metabolites identified via 1 H- NMR metabolomics rather than mass spectrometry, which is not yet available at sufficient scale. Mass spectrometry-based metabolomic analyses offers a broader representation of metabolites beyond lipid subclasses and there is a growing body of evidence that metabolites 526 detected by mass spectrometry are altered in EC patients^{12,75}. Future metabolomic studies using mass spectrometry should be conducted to comprehensively evaluate the role of metabolites as intermediates between adiposity and EC.

 Given the common shared genetic architecture, high correlation structure, and shared biology of metabolites, it is likely that a perturbation in any one metabolite does not happen in isolation. This is exemplified in recent work which has shown that the variance explained by 533 a metabolite's instrument is often greater for another^{45,73,76}. Here, we use a naïve approach to instrumentation in a hypothesis generating analysis; however, given many metabolite instruments include only a handful of SNPs, statistical methods aiming to measure the potential effects of pleiotropy (e.g., MR-Egger) do not always lead to meaningful results. This

 also applies to techniques designed to evaluate the effect of multiple correlated exposures (e.g., MVMR).

 In two-sample univariable MR analyses, sample overlap can bias estimates towards the confounded observational estimate (inflated type 1 error) in the presence of weak instruments in a manner proportional to the degree of overlap⁴². For our main analyses, we likely have 100% overlap between the adiposity and metabolites GWAS and up to a maximum 5% overlap for both of these with the overall EC GWAS. However, given bias due to sample 545 overlap is negligible in the presence of strong instruments⁷⁷ and that the results across sensitivity analyses using non-overlapping samples were generally consistent with the main 547 analyses, it is unlikely that estimates from our analyses are meaningfully impacted by such bias.

550 Another limitation is the unrepresentative nature of UK Biobank (initial response rate \sim 5%)⁷⁸ and the potential for selection bias. Given the age of the UK Biobank participants, the prevalence of statin use is high (~16% in UK Biobank vs ~11% in the general UK adult 553 population in 2014⁷⁹). For our MR analyses, we used summary-level data from the ¹H-NMR metabolite GWAS conducted using data from UK Biobank. This approach limits the capacity to fully explore the effects of other factors such as age and medication use (including statin use and HRT), which may influence the association between adiposity traits, metabolites and EC. Our analyses were limited to women of European ancestries; thus, these findings may 558 not apply to individuals of other ancestries. Furthermore, given that we used the same 1 H- NMR data from UK Biobank for both our MR and observational analyses examining the associations between adiposity traits and metabolites, these analyses cannot be considered independent. Replication of this study in other large cohort studies and in other ethnicities will allow a more robust characterisation of the metabolic profile associated with adiposity and the subsequent impact on EC.

Conclusions

 Our study suggests that higher BMI causes a higher risk of overall and all histological subtypes of EC and variation in numerous circulating metabolites. Several of these metabolites showed relationships consistent with an intermediate role in the effect of BMI on non-endometrioid

- 569 EC from two-step and MVMR MR analyses; however, further bioinformatic analyses
- 570 highlighted other potential shared mechanisms that could influence the risk of EC.

571

- DP receives consulting fees from Johnson & Johnson and Novo Nordisk and payments for
- lectures, presentations, and educational events from Johnson & Johnson, Medtronic, and
- Novo Nordisk.
- **Ethics approval**
-
- **Author contributions**
- MAL: conceptualization, data curation, formal analysis, investigation, methodology, project administration, validation, visualization, writing (original draft preparation), writing (review &
- editing)
-
- VT: conceptualization, data curation, formal analysis, investigation, methodology, project
- administration, validation, visualization, writing (original draft preparation), writing (review &
- editing)
-
- DP: resources, supervision, writing (review & editing)
-
- SW: writing (review & editing)
-
- LD: writing (review & editing)
-
- MJG: writing (review & editing)
-
- LJC: resources, supervision, writing (review & editing)
-
- KHW: resources, supervision, writing (review & editing)

NJT: conceptualization, resources, supervision, writing (review & editing)

Acknowledgments

 We would like to express our appreciation to UK Biobank participants and staff for providing the research community with this valuable source of data. This work used data from application number 16391.

Code and data availability

607 Univariable MR analyses were performed using TwoSampleMR 33 (version 0.4.22).; 608 multivariable MR analyses were performed using MVMR) 39 (version 0.3) R package; forest 609 plots were created using ggforestplot (version 0.1)⁸⁰ R package; circos plots were created 610 using EpiViz^{81–83} (version 0.1) R package. All publicly available data, code, and results used in this work are available on GitHub: 612 https://github.com/mattlee821/adiposity metabolites endometrial cancer. This includes all exposure data used in all MR analyses. The full summary statistics for BMI and WHR are available from the GIANT consortium (https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_ files) and Zenodo (https://zenodo.org/record/1251813#.Yk7O25PMIUE), data files 4, 5, 7, and 8. The full summary statistics for the endometrial cancer GWAS are available from the OpenGWAS database (https://gwas.mrcieu.ac.uk/datasets/); IDs for endometrial cancer GWAS: ebi-a-GCST006464, ebi-a-GCST006465, and ebi-a-GCST006466; This can be accessed via the TwoSampleMR (https://mrcieu.github.io/TwoSampleMR/) and ieugwasr (http://gwas-api.mrcieu.ac.uk/) R packages or directly from OpenGWAS in GWAS-VCF format⁵⁰. The full summary statistics for the ¹H-NMR metabolites will be made available at the University of Bristol data repository. The individual level data used in this work is not publicly available and can only be obtained from UK Biobank with an approved application.

Funding

 This work was supported by the Wellcome Trust through a Wellcome Trust Investigator award to NJT (202802/Z/16/Z, 2016-2023). MAL is funded by a Medical Research Council GW4 studentship (grant number: MR/R502340/1). NJT was a Wellcome Trust Investigator (202802/Z/16/Z, 2016-2023), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 217065/Z/19/Z), is supported by the University of Bristol NIHR Biomedical

 Research Centre (BRC-1215-2001), the MRC Integrative Epidemiology Unit (MC_UU_00011/1) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A29019). VT, NJT, SW, LD and MG are supported by the Cancer Research UK (grant number: PRCPJT- May22\100028). L.J.C. was supported by N.J.T.'s Wellcome Investigator Award (202802/Z/16/Z) 2016-2023, and by MC_UU_00032/1 since 2023. All authors work in the MRC Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (grant numbers: MC_UU_00011/1-7) and the University of Bristol. KHW is supported by the University of Bristol and Cancer Research UK [grant number RCCPDF\100007]. DJP has been funded by the Royal College of Surgeons of England. He receives consulting fees from Johnson & Johnson and Novo Nordisk and payments for lectures, presentations, and educational events from Johnson & Johnson, Medtronic, and Novo Nordisk. This research was funded in whole, or in part, by the Wellcome Trust [202802/Z/16/Z, 217065/Z/19/Z]. For the purpose of Open Access, the author has applied a 645 CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Disclaimer

 Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy or views of the International Agency for Research on Cancer/World Health Organization.

Conflict of interest

None declared

References

- 1. Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN. *CA Cancer J Clin* (2018) doi:10.3322/caac.21492.
- 2. Tavassoli, F. a & Devilee, P. Classification of Tumours. Pathology and Genetics of
- Tumours of the Breast and Female Genital Organs. *World Health Organization* (2003).
- 3. Amant, F. *et al.* Endometrial cancer. *The Lancet* **366**, 491–505 (2005).
- 4. Aune, D. *et al.* Anthropometric factors and endometrial cancer risk: A systematic review and dose-response meta-analysis of prospective studies. *Annals of Oncology* vol. 26 Preprint at https://doi.org/10.1093/annonc/mdv142 (2015).
- 5. Smith, G. D. & Ebrahim, S. 'Mendelian randomization': Can genetic epidemiology contribute to understanding environmental determinants of disease? *International Journal of Epidemiology* vol. 32 Preprint at https://doi.org/10.1093/ije/dyg070 (2003).
- 6. Painter, J. N. *et al.* Genetic risk score mendelian randomization shows that obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer. *Cancer Epidemiology Biomarkers and Prevention* **25**, (2016).
- 7. Lee, M. A. *et al.* Systematic review and meta-analyses: What has the application of Mendelian randomization told us about the causal effect of adiposity on health outcomes? *Wellcome Open Res* **7**, (2022).
- 8. O'Mara, T. A. *et al.* Identification of nine new susceptibility loci for endometrial cancer. *Nat Commun* **9**, 3166 (2018).
- 9. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation1. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011). *Cell* **144**, (2011).
- 10. Njoku, K. *et al.* Metabolomic Biomarkers for the Detection of Obesity-Driven Endometrial Cancer. *Cancers* vol. 13 Preprint at
- https://doi.org/10.3390/cancers13040718 (2021).
- 11. Yang, X. & Wang, J. L. The role of metabolic syndrome in endometrial cancer: A review. *Frontiers in Oncology* vol. 9 Preprint at
- https://doi.org/10.3389/fonc.2019.00744 (2019). 12. Dossus, L. *et al.* Prospective analysis of circulating metabolites and endometrial cancer risk. *Gynecol Oncol* **162**, 475–481 (2021).
- 13. Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* vol. 444 Preprint at https://doi.org/10.1038/nature05482 (2006).
- 14. Rosen, E. D. & Spiegelman, B. M. What we talk about when we talk about fat. *Cell* vol. 156 Preprint at https://doi.org/10.1016/j.cell.2013.12.012 (2014).
- 15. Würtz, P. *et al.* Metabolic Signatures of Adiposity in Young Adults: Mendelian Randomization Analysis and Effects of Weight Change. *PLoS Med* **11**, (2014).
- 16. Kliemann, N. *et al.* Metabolic signatures of greater body size and their associations with risk of colorectal and endometrial cancers in the European Prospective Investigation into Cancer and Nutrition. *BMC Med* **19**, (2021).
- 17. Relton, C. L. & Davey Smith, G. Two-step epigenetic mendelian randomization: A strategy for establishing the causal role of epigenetic processes in pathways to disease. *Int J Epidemiol* **41**, (2012).
- 18. Davey Smith, G. *et al.* STROBE-MR: Guidelines for strengthening the reporting of Mendelian randomization studies. *PeerJ Prepr* **7**, (2019).
- 19. von Elm, E. *et al.* The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. *International Journal of Surgery* **12**, (2014).

 40. Locke, A. E. *et al.* Genetic studies of body mass index yield new insights for obesity biology. *Nature* **518**, 197–206 (2015). 41. Bull, C. J. *et al.* Adiposity, metabolites, and colorectal cancer risk: Mendelian randomization study. *BMC Med* **18**, (2020). 42. Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two- sample Mendelian randomization. *Genet Epidemiol* **40**, (2016). 43. Shungin, D. *et al.* New genetic loci link adipose and insulin biology to body fat distribution. *Nature* **518**, 187–196 (2015). 44. Gallois, A. *et al.* A comprehensive study of metabolite genetics reveals strong pleiotropy and heterogeneity across time and context. *Nat Commun* **10**, (2019). 45. Smith, C. J. *et al.* Integrative analysis of metabolite GWAS illuminates the molecular basis of pleiotropy and genetic correlation. *Elife* **11**, (2022). 46. Lotta, L. A. *et al.* Cross-platform genetic discovery of small molecule products of metabolism and application to clinical outcomes. *Nat Genet* **53**, (2021). 47. Kamat, M. A. *et al.* PhenoScanner V2: An expanded tool for searching human genotype-phenotype associations. *Bioinformatics* **35**, (2019). 48. Staley, J. R. *et al.* PhenoScanner: A database of human genotype-phenotype associations. *Bioinformatics* **32**, (2016). 49. Raglan, O. *et al.* Risk factors for endometrial cancer: An umbrella review of the literature. *International Journal of Cancer* vol. 145 Preprint at https://doi.org/10.1002/ijc.31961 (2019). 50. Kyrgiou, M. *et al.* Adiposity and cancer at major anatomical sites: Umbrella review of the literature. *BMJ (Online)* vol. 356 Preprint at https://doi.org/10.1136/bmj.j477 (2017). 51. Kalliala, I. *et al.* Obesity and gynaecological and obstetric conditions: umbrella review of the literature. *BMJ* **359**, (2017). 52. Nead, K. T. *et al.* Evidence of a Causal Association between Insulinemia and Endometrial Cancer: A Mendelian Randomization Analysis. *J Natl Cancer Inst* **107**, (2015). 53. Freuer, D. *et al.* Body fat distribution and risk of breast, endometrial, and ovarian cancer: A two-sample mendelian randomization study. *Cancers (Basel)* **13**, (2021). 54. Hazelwood, E. *et al.* Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis. *BMC Med* **20**, (2022). 55. Renehan, A. G. *et al.* Incident cancer burden attributable to excess body mass index in 30 European countries. *Int J Cancer* **126**, (2010). 56. Bhaskaran, K. *et al.* Body-mass index and risk of 22 specific cancers: a population- based cohort study of 5·24 million UK adults. *The Lancet* **384**, (2014). 57. Sollberger, T. L., Gavrilyuk, O. & Rylander, C. Excess body weight and incidence of type 1 and type 2 endometrial cancer: The norwegian women and cancer study. *Clin Epidemiol* **12**, (2020). 58. Setiawan, V. W. *et al.* Type i and II endometrial cancers: Have they different risk factors? *Journal of Clinical Oncology* **31**, (2013). 59. Yang, H. P. *et al.* Endometrial cancer risk factors by 2 main histologic subtypes. *Am J Epidemiol* **177**, (2013). 60. Lauby-Secretan, B. *et al.* Body Fatness and Cancer — Viewpoint of the IARC Working Group. *New England Journal of Medicine* **375**, (2016). 61. O'Flanagan, C. H., Bowers, L. W. & Hursting, S. D. A weighty problem: Metabolic perturbations and the obesity-cancer link. *Hormone Molecular Biology and Clinical Investigation* vol. 23 Preprint at https://doi.org/10.1515/hmbci-2015-0022 (2015).

 62. Bell, J. A. *et al.* Effects of general and central adiposity on circulating lipoprotein, lipid, and metabolite levels in UK Biobank: A multivariable Mendelian randomization study. *The Lancet Regional Health - Europe* **21**, (2022). 63. Wulaningsih, W., Proitsi, P., Wong, A., Kuh, D. & Hardy, R. Metabolomic correlates of central adiposity and earlier-life body mass index. *J Lipid Res* **60**, (2019). 64. Riscal, R., Skuli, N. & Simon, M. C. Even Cancer Cells Watch Their Cholesterol! *Molecular Cell* vol. 76 Preprint at https://doi.org/10.1016/j.molcel.2019.09.008 (2019). 65. Omsjø, I. H. & Norum, K. R. CHOLESTEROL ESTERIFICATION IN HUMAN SECRETORY ENDOMETRIUM AND IN ENDOMETRIAL CANCER TISSUE: 815 Demonstration of Microsomal ACYL-COA-Cholesterol ACYL-transferase (ACAT) Activity. *Acta Obstet Gynecol Scand* **64**, (1985). 66. Ayyagari, V. N. *et al.* Evaluation of sterol-o-acyl transferase 1 and cholesterol ester levels in plasma, peritoneal fluid and tumor tissue of patients with endometrial cancer: A pilot study. *Oncol Lett* **25**, (2023). 67. Petersen, A. K. *et al.* On the hypothesis-free testing of metabolite ratios in genome- wide and metabolome-wide association studies. *BMC Bioinformatics* **13**, (2012). 68. Lindemann, K., Vatten, L. J., Ellstrøm-Engh, M. & Eskild, A. Serum lipids and endometrial cancer risk: Results from the HUNT-II study. *Int J Cancer* **124**, (2009). 69. Trabert, B. *et al.* Metabolic syndrome and risk of endometrial cancer in the United States: A study in the SEER-medicare linked database. *Cancer Epidemiology Biomarkers and Prevention* **24**, (2015). 70. Bjørge, T. *et al.* Metabolic syndrome and endometrial carcinoma. *Am J Epidemiol* **171**, (2010). 71. Seth, D. *et al.* Lipid profiles and the risk of endometrial cancer in the Swedish amoris study. *Int J Mol Epidemiol Genet* **3**, (2012). 72. Kho, P. F. *et al.* Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. *Int J Cancer* **148**, (2021). 73. Guida, F. *et al.* The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium. *PLoS Med* **18**, (2021). 74. Hamilton, F., Pedersen, K. M., Ghazal, P., Nordestgaard, B. G. & Smith, G. D. Low levels of small HDL particles predict but do not influence risk of sepsis. *Crit Care* **27**, (2023). 75. Audet-Delage, Y., Villeneuve, L., Grégoire, J., Plante, M. & Guillemette, C. Identification of metabolomic biomarkers for endometrial cancer and its recurrence after surgery in postmenopausal women. *Front Endocrinol (Lausanne)* **9**, (2018). 76. Surendran, P. *et al.* Rare and common genetic determinants of metabolic individuality and their effects on human health. *Nat Med* **28**, (2022). 77. Sadreev, I. I. *et al.* Navigating sample overlap, winner's curse and weak instrument bias in Mendelian randomization studies using the UK Biobank. *medRxiv* (2021). 78. Munafò, M. R., Tilling, K., Taylor, A. E., Evans, D. M. & Smith, G. D. Collider scope: When selection bias can substantially influence observed associations. *Int J Epidemiol* **47**, (2018). 79. Curtis, H. J., Walker, A. J., MacKenna, B., Croker, R. & Goldacre, B. Prescription of suboptimal statin treatment regimens: A retrospective cohort study of trends and variation in English primary care. *British Journal of General Practice* **70**, (2020). 80. Scheinin, I. , *et al.* ggforestplot: Forestplots of Measures of Effects and Their Confidence Intervals. https://nightingalehealth.github.io/ggforestplot/index.html, https://github.com/nighting alehealth/ggforestplot. (2023).

- 81. Lee M. A. *et al.* Epiviz: an implementation of Circos plots for epidemiologists.
- https://github.com/mattlee821/EpiViz (2020).
- 82. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. circlize implements and enhances circular visualization in R . *Bioinformatics* **30**, 2811–2812 (2014).
- 83. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847–2849 (2016).

Table 1. Baseline characteristics of UK Biobank participants included in our study

kg, kilograms; m², meters squared; SD, standard deviation; *p*, p value; HRT, hormone replacement therapy; N, sample size

Table 2. Observational estimates of the association between adiposity measures and endometrial cancer.

BMI, Body mass index; WHR, waist hip ratio; EC, endometrial cancer; OR, odds ratio; CI, confidence interval; *p*, p value

Figure 1. Study overview.

This study has four main analyses that were performed sequentially to estimate: (**Part I**) the effect of adiposity measures on EC, (**Part II**) the effect of adiposity measures on metabolites, (**Part III**) the effect of adiposity-associated metabolites and EC, and (**Part IV**) the potential intermediate role of adiposity-associated metabolites in the relationship between adiposity and EC (identified in **Part II** and **III**). Conventional observational analyses were performed for Part I-III; Mendelian randomization analyses were performed for Parts I-IV.

Figure 2. Mendelian randomization and observational estimates of the effect of BMI and WHR on endometrial cancer

The forest plot shows the estimates of the association between BMI and WHR with overall, endometrioid and non-endometrioid endometrial cancer from MR analyses (IVW method) using summary data from the Endometrial Cancer Association Consortium (ECAC) (n=12,906 endometrial cancer cases and 108,979 controls) and conventional observational analyses using individual level data from UK Biobank. Symbols represent point estimates from individual analyses. Horizontal lines represent 95% confidence intervals. Close circles represent *p*<0.05.

Figure 3. Mendelian randomization estimates of the effect of BMI on metabolites

The volcano plot shows the estimates of the effect of BMI on circulating metabolites from Mendelian randomization analyses. Metabolites associated with BMI at *p*<0.05 after correcting for multiple testing using Bonferroni correction are labelled.

Figure 4. Estimates of the causal effect of the BMI-associated metabolites on endometrial cancer risk

The forest plot shows the estimate of the causal effect of the BMI-associated metabolites and overall, endometrioid and non-endometrioid endometrial cancer based on two-sample MR (IVW method) from female-specific analyses. Only metabolites associated with endometrial cancer with a *p<*0.05 are shown in this figure. Symbols represent point estimates from individual analyses. Horizontal lines represent 95% confidence intervals. Squares represent metabolites that are positively associated with BMI and circles represent metabolites that are negatively associated with BMI.

Figure 5. Multivariable mendelian randomization estimates of the direct effect of BMI on endometrial cancer after adjustment for various BMIassociated metabolites

The forest plot shows the estimate of the direct causal effect of BMI on overall, endometrioid and non-endometrioid endometrial cancer based on multivariable MR analyses after adjustment for various metabolites that were associated with A) increased association with both BMI and endometrial cancer or B) decreased association with both BMI and endometrial cancer. Symbols represent point estimates of the direct effect of BMI on endometrial cancer after adjustment for various BMI-associated metabolites separately from multivariable MR analyses. Dotted red line represents the estimates of the indirect effect of BMI on endometrial cancer obtained from univariable IVW analyses. **endometrioid cancer − Non**

Figure 6. Traits associated with genetic instruments for metabolites underlying effect of BMI on endometrial cancer

A) The blue bars represent the proportion of genetic instruments associated with the top 30 traits identified in PhenoScanner for metabolites underlying the effect of BMI on endometrial cancer relative to the negative control (grey bars). The negative control was obtained by iteratively (N=100) looking up traits associated with instruments for 25 randomly selected metabolites not underlying the association between BMI and endometrial cancer; B) the histograms represent the frequency of the number of SNPs associated with trait from the negative control analysis. The red line represents the mean of the number of SNPs associated with each trait for the negative control and the blue line represents the number of SNPs associated with the metabolites underlying the effect of BMI on endometrial cancer risk associated with each trait.